Related Experiment Videos
Cellular modulation of acute graft-vs.-host disease
1Bone Marrow Transplant Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
Summary
Bone marrow transplantation (BMT) offers a cure for blood cancers, but graft-vs.-host disease (GVHD) is a major hurdle. Modulating immune cells, like natural killer cells, shows promise in preventing and treating GVHD.
Area of Science:
- Immunology
- Hematology
- Transplantation Science
Background:
- Bone marrow transplantation (BMT) is a curative option for hematologic malignancies.
- Severe graft-vs.-host disease (GVHD) is a significant complication limiting BMT application.
- Modulating the host/donor cellular environment is key for GVHD prevention and treatment.
Purpose of the Study:
- To review evidence on the immunoregulatory roles of host and donor cells in acute GVHD.
- To explore mechanisms of immune suppression in GVHD.
- To assess cellular-based therapies for GVHD treatment.
Main Methods:
- Literature review of studies on GVHD and immunomodulation.
- Examination of cell phenotypes associated with immune suppression (e.g., null cells, double negative T lymphocytes, NK cells).
- Analysis of data on cellular therapies for acute GVHD.
Main Results:
- Immunoregulatory cells, including natural suppressor and veto cells, are implicated in inhibiting alloresponses.
- Specific cell types like null cells, double negative T lymphocytes, and natural killer cells exhibit suppressive activity.
- Autologous cellular therapies show promise in reversing GVHD post-transplantation.
Conclusions:
- Host and donor cells play a crucial immunoregulatory role in modulating acute GVHD.
- Understanding these cellular mechanisms is vital for improving BMT outcomes.
- Cellular-based interventions represent a promising strategy for managing GVHD.